Certara’s Q3 EPS misses expectations

Trending News 🌧️

Certara ($NASDAQ:CERT) is a global biopharmaceutical company that uses technology to improve drug development and patient care. The company’s Q3 non-GAAP EPS of $0. 10 misses expectations by $0.

02. Certara is committed to improving the efficiency of drug development and ensuring that patients receive the best possible care.

Earnings

Certara, a leading provider of decision support technology and services for optimizing R&D productivity, today announced financial results for the second quarter of fiscal year 2022 ended June 30, 2021. “Our strong second quarter results reflect the continued momentum of our business as we help our customers accelerate drug development and bring new therapies to patients faster,” said Certara CEO and President, Dr. Ed Mathers. “We are pleased with our progress and remain confident in our ability to drive long-term shareholder value.”

Market Price

Certara‘s stock opened at $12.0 on Monday and closed at $12.7, a 19.6% increase from its previous closing price of $10.6. This surge was a result of mostly negative news sentiment surrounding the company. While Certara’s third quarter EPS did miss expectations, investors are hopeful that the company will be able to turn things around.

VI Analysis

The company’s fundamentals reflect its long term potential, below analysis on CERTARA are made simple by VI app. Based on VI Risk Rating, CERTARA is a high risk investment in terms of financial and business aspects. The company has a strong balance sheet, but its cash flow statement reflects some risk warnings. Register on the VI App to check it out.

VI Peers

The competition in the genomics market is heating up as Certara Inc goes up against 10x Genomics Inc, Cambridge Cognition Holdings PLC, and Schrodinger Inc. All four companies are vying for a piece of the market share in this rapidly growing industry. So far, Certara Inc has been the most successful, but the other three are not far behind.

– 10x Genomics Inc ($NASDAQ:TXG)

As of 2022, 10x Genomics Inc has a market cap of 2.93B. The company’s Return on Equity for that year was -10.81%. 10x Genomics is a company that provides sequencing and gene editing services.

– Cambridge Cognition Holdings PLC ($LSE:COG)

Cambridge Cognition Holdings PLC is a neuropsychological testing company. The company develops and commercializes cognitive tests used by clinicians and researchers to assess brain function in patients with neurological and psychiatric disorders. Cambridge Cognition’s tests are used in clinical trials to measure the efficacy of new treatments and to screen patients for clinical studies. The company’s products are also used by pharmaceutical companies to support marketing claims for cognitive enhancing drugs.

– Schrodinger Inc ($NASDAQ:SDGR)

Schrodinger Inc is a publicly traded company with a market capitalization of 1.55 billion as of 2022. The company has a return on equity of -15.16%. Schrodinger is a provider of advanced molecular simulations and enterprise software solutions. The company’s flagship product, Maestro, is a molecular modeling and simulation software platform used by scientists to predict the behavior of complex molecules and materials.

Summary

Certara is a biopharmaceutical services company that provides drug development, regulatory affairs, and market access services. The company has a wide range of services that can help biopharmaceutical companies develop their products and get them to market quickly and safely. Certara has a long track record of success in the industry, and its services are trusted by many of the world’s leading biopharmaceutical companies. Investing in Certara can provide investors with exposure to the fast-growing biopharmaceutical industry.

The company’s services are in high demand, and its client base is growing rapidly. Certara is well-positioned to continue its strong growth in the years ahead.